Literature DB >> 23104051

Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy.

Piero Fossati1, Silvia Molinelli, Naruhiru Matsufuji, Mario Ciocca, Alfredo Mirandola, Andrea Mairani, Junetsu Mizoe, Azusa Hasegawa, Reiko Imai, Tadashi Kamada, Roberto Orecchia, Hirohiko Tsujii.   

Abstract

In carbon ion radiotherapy there is an urgent clinical need to develop objective tools for the conversion of relative biological effectiveness (RBE)-weighted doses based on different models. In this work we introduce a clinically oriented method to compare NIRS-based and LEM-based GyE systems, minimizing differences in physical dose distributions between treatment plans. Carbon ion plans were optimized on target volumes of cubic and spherical shapes, for RBE-weighted dose prescription levels ranging from 3.6 to 4.4 GyE. Plans were calculated for target sizes from 4 to 12 cm defining three beam geometries: single beam, opposed beam and orthogonal beam configurations. The two treatment planning systems currently employed in clinical practice were used, providing the NIRS-based and LEM-based GyE calculations. Physical dose distributions of NIRS-based and LEM-based treatment plans were compared. LEM-based prescription doses that minimize differences in physical dose distributions between the two systems were found. These doses were compared with the mean RBE-weighted dose obtained with a Monte Carlo code (FLUKA) interfaced with LEM I. In the investigated dose range, LEM-based RBE-weighted prescription doses, that minimize differences with NIRS plans, should be higher than NIRS reported prescription doses. The optimal dose depends on target size, shape and position, number of beams and dose level. The opposed beam configuration resulted in the smallest average prescription dose difference (0.45 ± 0.09 GyE). The second approach of recalculating NIRS RBE-weighted dose with a Monte Carlo code interfaced with LEM resulted in no significant difference with the results obtained from the planning study. The delivery of a voxel by voxel iso-effective plan, if different RBE models are employed, is not feasible; it is however possible to minimize differences in a treatment plan with the simple approach presented here. Dose prescription ultimately represents a clinical task under the responsibility of the radiation oncologist, the presented analysis intends to be a quantitative and objective way to assist the clinical decision.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104051     DOI: 10.1088/0031-9155/57/22/7543

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  21 in total

1.  Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis.

Authors:  Amelia Barcellini; Viviana Vitolo; Lorenzo Cobianchi; Andrea Peloso; Alessandro Vanoli; Alfredo Mirandola; Angelica Facoetti; Maria Rosaria Fiore; Alberto Iannalfi; Barbara Vischioni; Francesco Cuccia; Sara Ronchi; Maria Bonora; Giulia Riva; Rachele Petrucci; Emma D'Ippolito; Francesca Dal Mas; Lorenzo Preda; Francesca Valvo
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Applications of nanodosimetry in particle therapy planning and beyond.

Authors:  Antoni Rucinski; Anna Biernacka; Reinhard Schulte
Journal:  Phys Med Biol       Date:  2021-12-10       Impact factor: 3.609

3.  Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.

Authors:  Alberto Iannalfi; Emma D'Ippolito; Giulia Riva; Silvia Molinelli; Sara Gandini; Gisela Viselner; Maria Rosaria Fiore; Barbara Vischioni; Viviana Vitolo; Maria Bonora; Sara Ronchi; Rachele Petrucci; Amelia Barcellini; Alfredo Mirandola; Stefania Russo; Alessandro Vai; Edoardo Mastella; Giuseppe Magro; Davide Maestri; Mario Ciocca; Lorenzo Preda; Francesca Valvo; Roberto Orecchia
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

4.  Review of carbon ion radiotherapy for skull base tumors (especially chordomas).

Authors:  Jun-Etsu Mizoe
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-20

Review 5.  Clinical trials involving carbon-ion radiation therapy and the path forward.

Authors:  Ann A Lazar; Reinhard Schulte; Bruce Faddegon; Eleanor A Blakely; Mack Roach
Journal:  Cancer       Date:  2018-10-11       Impact factor: 6.860

Review 6.  Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan.

Authors:  Osama Mohamad; Hirokazu Makishima; Tadashi Kamada
Journal:  Cancers (Basel)       Date:  2018-03-06       Impact factor: 6.639

7.  The Emerging Role of Carbon-Ion Radiotherapy.

Authors:  Daniel K Ebner; Tadashi Kamada
Journal:  Front Oncol       Date:  2016-06-07       Impact factor: 6.244

8.  Surgical spacer placement prior carbon ion radiotherapy (CIRT): an effective feasible strategy to improve the treatment for sacral chordoma.

Authors:  Cobianchi Lorenzo; Peloso Andrea; Vischioni Barbara; Panizza Denis; Fiore Maria Rosaria; Fossati Piero; Vitolo Viviana; Iannalfi Alberto; Ciocca Mario; Silvia Brugnatelli; Dominioni Tommaso; Dario Bugada; Maestri Marcello; Alessiani Mario; Valvo Francesca; Orecchia Roberto; Dionigi Paolo
Journal:  World J Surg Oncol       Date:  2016-08-09       Impact factor: 2.754

9.  Fast robust dose calculation on GPU for high-precision 1H, 4He, 12C and 16O ion therapy: the FRoG platform.

Authors:  Stewart Mein; Kyungdon Choi; Benedikt Kopp; Thomas Tessonnier; Julia Bauer; Alfredo Ferrari; Thomas Haberer; Jürgen Debus; Amir Abdollahi; Andrea Mairani
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

10.  Carbon Ion Dose Constraints in the Head and Neck and Skull Base: Review of MedAustron Institutional Protocols.

Authors:  Piero Fossati; Ana Perpar; Markus Stock; Petra Georg; Antonio Carlino; Joanna Gora; Giovanna Martino; Eugen B Hug
Journal:  Int J Part Ther       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.